Published in Proc Natl Acad Sci U S A on November 25, 1997
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Diffusion in brain extracellular space. Physiol Rev (2008) 5.34
Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep (2006) 4.06
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science (2010) 3.98
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron (2005) 3.72
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci (2009) 2.85
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A (2006) 2.66
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci (2008) 2.57
Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.56
Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A (2006) 2.45
Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A (2012) 2.36
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A (2009) 2.27
Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. Proc Natl Acad Sci U S A (2004) 2.20
Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A (1999) 2.16
Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol (1999) 2.10
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A (2010) 1.97
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 1.90
Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol (2001) 1.87
Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci U S A (2003) 1.86
Alzheimer's disease. Cold Spring Harb Perspect Biol (2011) 1.81
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol (2007) 1.77
Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol (2005) 1.77
Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol (2004) 1.70
Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A (2005) 1.67
Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition. J Neurosci (2011) 1.66
Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A (2008) 1.64
Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro (2010) 1.58
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet (2014) 1.56
Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr (2004) 1.53
Inhibition of amyloid-β plaque formation by α-synuclein. Nat Med (2015) 1.52
Microglial dysfunction in brain aging and Alzheimer's disease. Biochem Pharmacol (2014) 1.52
Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One (2013) 1.48
Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J Neurosci (2010) 1.48
Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci (2014) 1.47
Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A (2005) 1.47
Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 1.47
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A (2003) 1.46
Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation (2005) 1.45
Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci (2008) 1.44
Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid. Brain (2014) 1.43
Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.42
Cell division in the CNS: protective response or lethal event in post-mitotic neurons? Biochim Biophys Acta (2006) 1.41
Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A (2011) 1.39
Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol (2000) 1.39
Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One (2010) 1.37
Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci U S A (2003) 1.37
Changes in extracellular space size and geometry in APP23 transgenic mice: a model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.35
Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration. J Alzheimers Dis (2010) 1.34
Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol (2001) 1.34
Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc Natl Acad Sci U S A (2014) 1.34
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest (2012) 1.32
Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci (2008) 1.29
NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.27
Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol (2012) 1.26
Endoplasmic reticulum chaperones inhibit the production of amyloid-beta peptides. Biochem J (2007) 1.24
Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev (2009) 1.24
Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci (2008) 1.23
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther (2009) 1.23
Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.21
Optical monitoring of brain function in vivo: from neurons to networks. Pflugers Arch (2006) 1.21
Transgenic models of Alzheimer's disease: learning from animals. NeuroRx (2005) 1.21
Replacement of brain-resident myeloid cells does not alter cerebral amyloid-β deposition in mouse models of Alzheimer's disease. J Exp Med (2015) 1.21
Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Lond B Biol Sci (1999) 1.21
Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice. EMBO Rep (2013) 1.20
APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct Funct (2009) 1.20
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets (2009) 1.20
In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci (2011) 1.19
Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci (2015) 1.18
Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice. Proc Natl Acad Sci U S A (2014) 1.18
Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One (2012) 1.18
Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers. ASN Neuro (2009) 1.17
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol (1999) 1.17
Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am J Pathol (1999) 1.17
beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol (2001) 1.17
Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis (2010) 1.17
Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging (2014) 1.16
Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol (2010) 1.16
Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol (2005) 1.15
The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel (2010) 1.15
Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses. Neurobiol Aging (2008) 1.14
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener (2007) 1.13
Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn Mem (2002) 1.13
Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol (2011) 1.13
Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem (2009) 1.12
Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol (2004) 1.11
Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat (2007) 1.11
Microglia in Alzheimer's disease and transgenic models. How close the fit? Am J Pathol (1999) 1.09
Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc Natl Acad Sci U S A (2007) 1.08
The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain. Acta Neuropathol (2011) 1.06
Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. Nat Commun (2012) 1.06
The value of incomplete mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 1.06
Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation (2009) 1.04
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron (1989) 8.04
RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell (1991) 6.97
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science (1993) 3.95
Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung (1971) 3.71
A neuronal antigen in the brains of Alzheimer patients. Science (1986) 3.49
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett (1995) 3.15
Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol (1994) 3.13
The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J (1992) 3.04
Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron (1996) 2.89
A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol (1994) 2.83
Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci (1996) 2.69
beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron (1995) 2.56
The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem (1996) 2.41
Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem (1992) 2.40
Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci (1993) 2.10
Microglia in degenerative neurological disease. Glia (1993) 1.89
Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature (1991) 1.79
Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nat Genet (1993) 1.74
Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res (1994) 1.58
Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J Neurosci (1997) 1.55
A modified histochemical technique to visualize acetylcholinesterase-containing axons. J Histochem Cytochem (1985) 1.49
Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol (1996) 1.27
APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. J Biol Chem (1994) 1.18
Alzheimer's disease: a description of the structural lesions. Brain Pathol (1991) 1.15
Expression of APP in transgenic mice: a comparison of neuron-specific promoters. Neurobiol Aging (1996) 1.12
Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience (1989) 1.10
Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Proc Natl Acad Sci U S A (1992) 1.09
Astrocytes and the plaques of Alzheimer's disease. Neurology (1990) 1.08
Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann Neurol (1987) 1.06
Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for beta-APP751. Proc Natl Acad Sci U S A (1995) 1.02
Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid. J Neurosci Res (1996) 0.99
Acetylcholinesterase fibers and the development of senile plaques. Brain Res (1987) 0.99
Differential regional and cellular distribution of beta-amyloid precursor protein messenger RNAs containing and lacking the Kunitz protease inhibitor domain in the brain of human, rat and mouse. Neuroscience (1993) 0.98
Identification of the 5-hydroxytryptamine2C receptor as a 60-kDa N-glycosylated protein in choroid plexus and hippocampus. J Neurochem (1995) 0.91
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (1989) 7.52
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 7.34
RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell (1993) 5.62
Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature (1989) 5.48
Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (1990) 5.41
Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science (1999) 4.56
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
A family of AMPA-selective glutamate receptors. Science (1990) 3.85
The bHLH protein PTF1-p48 is essential for the formation of the exocrine and the correct spatial organization of the endocrine pancreas. Genes Dev (1998) 3.42
The influence of antigen organization on B cell responsiveness. Science (1993) 3.32
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science (2000) 3.07
Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol (1996) 2.96
Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet (1998) 2.84
Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature (1998) 2.56
Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur J Immunol (1997) 2.53
Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci (2000) 2.49
The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol (1995) 2.47
Neuron loss in APP transgenic mice. Nature (1998) 2.38
Peripheral deletion of self-reactive B cells. Nature (1991) 2.34
Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol (1999) 2.33
Targeted mutation of plakoglobin in mice reveals essential functions of desmosomes in the embryonic heart. J Cell Biol (1996) 2.27
Efficient targeting of the IL-4 gene in a BALB/c embryonic stem cell line. Transgenic Res (1996) 2.23
Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors. J Struct Biol (2000) 2.19
Different structural systems of the nucleus are targets for SV40 large T antigen. Cell (1983) 2.18
Formation of cytoskeletal elements during mouse embryogenesis. Intermediate filaments of the cytokeratin type and desmosomes in preimplantation embryos. Differentiation (1980) 2.17
Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A (1999) 2.16
Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol (1999) 2.10
Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res (2002) 2.08
Preparation of nuclear matrices from cultured cells: subfractionation of nuclei in situ. J Cell Biol (1984) 2.07
Neuropathology in mice expressing human alpha-synuclein. J Neurosci (2000) 2.06
IL-4-deficient Balb/c mice resist infection with Leishmania major. J Exp Med (1996) 2.03
CD8+ T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur J Immunol (1994) 2.00
Amyloid fibril formation from full-length and fragments of amylin. J Struct Biol (2000) 1.95
Adverse effects of tribromoethanol as used in the production of transgenic mice. Lab Anim (1998) 1.94
T cell tolerance to Mlsa encoded antigens in T cell receptor V beta 8.1 chain transgenic mice. EMBO J (1989) 1.94
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Resistance of Fc receptor- deficient mice to fatal glomerulonephritis. J Clin Invest (1998) 1.88
Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol (2006) 1.87
Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci (2000) 1.84
Alzheimer's paired helical filaments share epitopes with neurofilament side arms. EMBO J (1986) 1.81
Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol (1996) 1.80
The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J (1989) 1.79
Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J (1995) 1.77
Familial Tetralogy of Fallot caused by mutation in the jagged1 gene. Hum Mol Genet (2001) 1.75
The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J (2003) 1.75
Recurrent abdominal pain: a potential precursor of irritable bowel syndrome in adolescents and young adults. J Pediatr (1998) 1.71
Establishment of a germ-line competent C57BL/6 embryonic stem cell line. Exp Cell Res (1991) 1.70
Thiazide-induced hypokalemia. Association with acute myocardial infarction and ventricular fibrillation. JAMA (1978) 1.68
Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Calpha. Proc Natl Acad Sci U S A (1998) 1.68
Distinct sequence of negative or positive selection implied by thymocyte T-cell receptor densities. Nature (1990) 1.61
Neuritic plaques in senile dementia of Alzheimer type: a Golgi analysis in the hippocampal region. Brain Res (1983) 1.60
CONTROL OF ETHANOL DEHYDROGENASE LEVELS IN AEROBACTER AEROGENES. J Bacteriol (1961) 1.56
The hemodynamic response to chronic anemia. Circulation (1969) 1.56
[Bridging peripheral nerve defects by means of nerve conduits]. Chirurg (2007) 1.52
Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci (2001) 1.51
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging (2002) 1.50
Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem (2001) 1.49
Activity-regulated cytoskeletal-associated protein is localized to recently activated excitatory synapses. Neuroscience (2004) 1.49
Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health (2001) 1.48
Involvement of both T cell receptor V alpha and V beta variable region domains and alpha chain junctional region in viral antigen recognition. Eur J Immunol (1991) 1.47
Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol (1999) 1.45
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol (1996) 1.43